Endocrine Abstracts

There are much controversy adjuvant radioiodine treatment (131-I-th) in intermediate or low risk patients with lymph node micrometastases. The first results of ESTIMABL2 trial showed no radioiodine benefit in low risk DTC, however intermediate patients were not included in this study.Aim: Observational study was to evaluate effects of 131-I-th in intermediate/low risk DTC patients.Patients: There were 342 women (85%), the median ag...

Introduction: According to the literature, the CRH test has the highest specificity in excluding ECS (ACTH 93.9%, cortisol 89.4%). A combination of the high dose dexamethasone test (HDDST) and CRH/desmopressin test (CRH/desmopressinT) is used to increase the discriminatory capacity in ACTH-dependent CS.Objectives: This study aims to investigate the response to dynamic tests in ECS patients.Methods: 35 consecutive ECS patients were ...

Background: Overt hypercortisolism is highly associated with venous thromboembolism. Patients with Cushing’s syndrome (CS) typically show an alteration of the intrinsic coagulation pathway, especially an increase in factor VIII (f-VIII), and increased levels of coagulation inhibitors (i.e., antithrombin III) as a compensatory response. Mild autonomous cortisol secretion (MACS) has been variably associated with higher risk of cardiovascular events and mortality compared to...

Background: Both diabetes mellitus and hyperglycemia are reported to be strong risk factors for poor outcome(s) in patients hospitalized for COVID-19. However, their relative roles in affecting patient prognosis are under debate.Aims: To evaluate the independent influence of known diabetes mellitus and hyperglycemia on death/admission to intensive care unit (ICU) in patients hospitalized for COVID-19 during the first wave of SARS-Co-V2 pandemic.<p cl...

Background: Neuroendocrine tumors (NETs) are characterized by long survival and slow progression. In the clinical practice adifferent types of endocrine-metabolic disorders can occur. Such disorders are either comorbidities related to the neoplasm or side effects of specific oncological treatments. The aim of this study is to evaluate type and prevalence of the endocrine-metabolic disorders in patients with gastroenteropancreatic (GEP) and lung NETs.Mate...

Case Summary: In May 2018, a 22-year-old man was admitted to the Emergency Room of Polyclinic Umberto I Hospital of Rome, because of progressive headaches and binocular diplopia. Brain MRI revealed a heterogeneous T1WI-hypointense and T2WI-hyperintense mass of 40x28x25 mm (CC, LL, AP) including calcification areas in the left paramedian region of the clivus invading the homolateral cavernous sinus. The patient underwent partial tumour resection via infratemporal approach and a...

Background: Craniopharingioma patients frequently experience severe obesity, unresponsive to caloric restriction or lifestyle modifications. Recently very-low-ketogenic-diets (VLCKD) proved to be a promising lifestyle intervention for obesity management, but no data are available regarding their effect on hypothalamic obesity (HO).Introduction: We present the outcome of VLCKD protocol applied in young patients with HO following neurosurgery for craniopha...

Background: Very low-calorie ketogenic diet (VLCKD) was shown to be effective in reducing weight and insulin resistance (IR) in obese patients. Considering that IR is very common in women with polycystic ovary syndrome (PCOS), and that IR worsens hyperandrogenism, ovulatory disfunction, and body fat accumulation, conceivably VLCKD could alleviate PCOS manifestations in the obese phenotype.Objective: This study compared the effects of a commercial VLCKD (...

Objectives: The aim was to evaluate the iodine nutritional status in pregnant women residing in Veneto region and its associations with diet, iodine supplements and social status (nationality and education).Methods: 292 consecutive pregnant women at the third trimester of pregnancy were enrolled (≥18 years old, and resident in Veneto). Exclusion criteria were a personal history of thyroid disease and the refusal of the informed consent. Every woman...

Paltusotine is an investigational oral, once-daily, non-peptide, SST2 agonist in development for the treatment of acromegaly and neuroendocrine tumors. Interim analysis results from subjects with acromegaly treated with paltusotine for up to 2 years in ACROBAT Advance (NCT04261712), an ongoing, open-label extension study are reported here. Prior to Advance, subjects previously completed one of two Phase 2 parent studies, Evolve (NCT03792555, with normal IGF-1 using injected lo...